Funder: Eli Lilly and Company
Due Dates (Anticipated): February 2027
Funding Amounts: Amount varies by proposal; financial support and/or study drug provided as appropriate for investigator-initiated clinical research.
Summary: Supports investigator-led research on the efficacy of lebrikizumab for fibrosing skin conditions, with independent study design and conduct.
Key Information: This is a forecasted opportunity; dates and details may change—review the program page for current information.